N4 Pharma Broker Offer to raise a maximum of £1 million

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an opportunity for shareholders and other investors who did not participate in the fundraising announced today to invest in the Company.

·    N4 Pharma (AIM: N4P) announces a Broker Offer through Turner Pope Investments (TPI) Limited

·    The Issue Price of the Broker Offer is 2 pence per new ordinary share

·    Existing Shareholders or other interested parties who wish to register their interest in participating in the Broker Offer should click on the following TPI platform link: N4 Pharma Broker Offer

·    The Broker Offer has an initial expected value of £0.25 million but may be extended, with the express agreement of the Company, to £1.0 million in the event the Broker Offer is oversubscribed

·    All bids communicated to TPI under the Broker Offer are subject to review and acceptance by the Company and TPI and priority will be given to existing shareholders in the event of oversubscription

·    The Broker Offer remains open until 4:30 p.m. on Monday, 21 November 2022

Under the Placing Agreement, TPI has been granted an option in the form of a broker offer (“Broker Offer”) under which TPI will, as agent for the Company, invite subscriptions for additional new ordinary shares of 0.4p each in the Company (“Broker Offer Shares”) with an initial expected value of £0.25 million at the issue price of 2p (“Issue Price”).  The Broker Offer may be extended, with the express agreement of the Company, to £1.0 million in the event the Broker Offer is oversubscribed.  Accordingly, the maximum number of Broker Offer Shares to be issued under the Broker Offer at the Issue Price is 50,000,000.

The Broker Offer opens immediately and will close at 4.30pm on Monday, 21 November 2022.

As far as is practical, participation in the Broker Offer will be prioritised for shareholders (direct or indirect) on the register at the close of business on 17 November 2022. 

To subscribe for Broker Offer Shares, Existing Shareholders or other interested parties who wish to register their interest in participating in the Broker Offer should click on the following link : N4 Pharma Broker Offer

A further announcement will be made following the end of the period during which the Broker Offer is open.  If the Broker Offer is not fully subscribed by 4.30 p.m. on 21 November 2022, orders from eligible investors will be satisfied in full, and the balance of the Broker Offer shall lapse.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    N4 Pharma

    More articles like this

    N4 Pharma

    N4 Pharma updates on Nuvec AAV Viral Vector research

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, has provided a further successful update on its ongoing research work into the use of Nuvec® to

    N4 Pharma

    N4 Pharma plc Nuvec Oral Delivery Update

    N4 Pharma Plc (LON: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided a positive update on its ongoing oral delivery research work. The Company through its research

    N4 Pharma

    N4 Pharma plc Nuvec® R&D and Strategy Update

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an encouraging update on its ongoing in vitro siRNA research work. The Company’s double loaded siRNA work is

    N4 Pharma

    N4 Pharma launch Interactive Investor Hub

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced the launch of the N4 Pharma Interactive Investor Hub. For both existing and prospective shareholders,

    N4 Pharma

    N4 Pharma updated investor presentation

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that an updated investor presentation incorporating the Company’s acquisition of a 71% interest in Nanogencis

    N4 Pharma

    N4 Pharma acquires of a controlling interest in Nanogenics

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for oncology, gene therapy and vaccines, has announced the acquisition of a controlling interest, through a subscription for new ordinary shares, in Nanogenics Limited,

    N4 Pharma

    N4 Pharma granting of patent application in the United States

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced two operational updates. Granting of further US patent The University of Queensland has informed the Company that

    N4 Pharma

    N4 Pharma updates on in vitro results for Nuvec®

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided a further update on its ongoing in vitro siRNA research work. BCL-2 assay has been established Further

    N4 Pharma

    N4 Pharma Nuvec well suited for working with siRNA

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its ongoing siRNA research work. The Company has completed the single loading

    N4 Pharma

    N4 Pharma well funded to deliver its siRNA programme

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced its audited results for the year ended 31 December 2022. Highlights: • Nuvec® as a

    N4 Pharma

    N4 Pharma AGM to be held on 3 April 2023

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that its Annual Report and Accounts for the year ended 31 December 2022 and Notice

    N4 Pharma

    N4 Pharma raises £1million through a placing

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that it has raised £1 million (before expenses) through a placing of 50,000,000 new ordinary

    N4 Pharma

    N4 Pharma updates on patent filing

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its patent application for Nuvec®, filed in March 2020 (no. PCT/GB2021/050960 Gene